Scholarlink

Poly ADP-ribose Polymerases (PARP) inhibitors are an important new treatment option in the management of metastatic castrate resistant prostate cancer. The main mechanism of action is by inducing synthetic lethality in cells with underlying deficiencies in homologous recombination repair (HRR) of DNA. Response rates are highest in men with germline or somatic BRCA 1/2 mutations. Examples of PARP inhibitors include olaparib, rucaparib, niraparib and talazoparib. Rucarib and nirapirib are limited to those with pathogenic variants in BRCA 1/2, while olaparib and talazoprarib may be used in patients with several genes showing HRR deficiency.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PARP Inhibitors

  • 章节

  • 发表日期：

    2026年

查看全文
  • Hammad Hammad,
  • Chinnamani Eswar

摘要

Poly ADP-ribose Polymerases (PARP) inhibitors are an important new treatment option in the management of metastatic castrate resistant prostate cancer. The main mechanism of action is by inducing synthetic lethality in cells with underlying deficiencies in homologous recombination repair (HRR) of DNA. Response rates are highest in men with germline or somatic BRCA 1/2 mutations. Examples of PARP inhibitors include olaparib, rucaparib, niraparib and talazoparib. Rucarib and nirapirib are limited to those with pathogenic variants in BRCA 1/2, while olaparib and talazoprarib may be used in patients with several genes showing HRR deficiency.